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The RhoA GTPase is involved in regulating actin cytoskeletal organization, gene expression, cell 
proliferation, and survival. We report here that p115-RhoGEF, a specific guanine nucleotide 
exchange factor (GEF) and activator of RhoA, modulates HIV-1 replication. Ectopic expression of 
p115-RhoGEF or Gα13, which activates p115-RhoGEF activity, leads to inhibition of HIV-1 
replication. RhoA activation is required and the inhibition affects HIV-1 gene expression. The 
RhoA effector activity in inhibiting HIV-1 replication is genetically separable from its activities in 
transformation of NIH3T3 cells, activation of serum response factor, and actin stress fiber 
formation. These findings reveal that the RhoA signal transduction pathway regulates HIV-1 
replication and suggest that RhoA inhibits HIV-1 replication via a novel effector activity.
The Rho family of small GTPases (RhoA, Rac1, and Cdc42) regulates a variety of important 
cell signaling and growth control pathways (1–3). In response to extracellular stimulation, 
activated Rho GTPases are involved in actin cytoskeletal reorganization (4–6), activation of 
transcription factors such as serum response factor (SRF)3 (7) or NF-κB (8), and cell cycle 
progression (9, 10). The molecular mechanisms of the pleotropic effects of Rho GTPases are 
not clear and may reflect the complex nature of Rho GTPase regulation (3). Like other 
members of the Ras superfamily GTPases, Rho GTPases bind and hydrolyze GTP, cycling 
between a biologically active GTP-bound and an inactive GDP-bound form. GTPase-
activating proteins (GAPs) increase the low intrinsic rate of GTP hydrolysis of Rho proteins, 
thus converting them to the inactive configuration (inhibitors). The guanine nucleotide 
dissociation inhibitors bind to Rho proteins and lock them into their existing nucleotide-
bound state, thus acting as both positive and negative regulators of Rho proteins. A third 
class of regulatory proteins, guanine nucleotide exchange factors (GEFs; also called Dbl 
family proteins; Refs. 3 and 11), stimulate the exchange of GDP for GTP on Rho proteins, 
thus converting them into the biologically active forms (activators).
In addition, the diverse functions of RhoA are mediated by the association of GTP-bound 
RhoA with a number of RhoA effector proteins (12). These include two families of serine/
threonine kinases. The Rho kinase (ROK) and other ROK family kinases (13, 14) are 
required for RhoA-mediated cell transformation, SRF activation (15), and actin stress fiber 
formation. Protein kinase N and its related kinases also interact with GTP-RhoA, but their 
effector functions are not clear (16). In addition, several adaptor proteins preferentially bind 
GTP-RhoA. They include rhophilin (17), rho-tekin (18), kinectin (19), and citron (20). The 
specific functions of the adaptor effectors are not clear. Using RhoA effector domain 
mutants, it has recently been reported that distinct effectors are involved in RhoA-mediated 
transformation of NIH3T3 cells, SRF activation, and actin stress fiber formation (21, 22).
In T cells, Rho GTPases have been implicated in T cell development and T cell activation 
(23). Rac1 has been implicated in mediating signals from both TCR and costimulatory 
receptor CD28 during T cell activation (24). Cdc42 is reported to organize actin polarization 
of T cells toward APC (25), and defects in its signaling lead to T cell unresponsiveness (26). 
RhoA has recently been implicated in mediating CD3/CD28 signals to promote IL-2 
production (27). Recently, the RhoA GTPase has been shown to promote survival of pro- 
and early pre-thymocytes and cell cycle progression of late pre-thymocytes (28).
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HIV-1 replication is modulated by a number of cellular signaling pathways regulated by 
both host and viral factors (29). For example, T cell activation is required for efficient 
HIV-1 replication in resting T cells (30, 31). Activation of transcription factors such as NF-
κB (32) and NF-ATc (33, 34) leads to enhanced HIV gene expression and replication. 
Although the Rho GTPases have been implicated in T cell activation (23, 28, 35), little is 
known about how Rho GTPases affect HIV-1 replication. The transmembrane glycoprotein 
(TM or gp41) of HIV-1 contains a long cytoplasmic domain (gp41C). Its function is not 
clear but has been implicated in regulating HIV-1 replication and cytopathogenicity (36). 
We recently demonstrated that gp41C interacted with the C-terminal domain of p115-
RhoGEF (37), which is a specific GEF and activator of the RhoA GTPase (38). We report 
here that both p115-RhoGEF and its specific activator, Gα13, can inhibit HIV-1 replication. 
RhoA activation is required for the inhibition of HIV-1 replication. The RhoA effector 
activity involved is genetically separable from those involved in transformation of NIH3T3 
cells, activation of SRF, and actin stress fiber formation.
Materials and Methods
Reagents, plasmids, and cell lines
All p115-RhoGEF derivatives, including p115FL (1-912), p115dN (249-912), p115dC 
(249-802), p115dDH (p115 with an internal deletion from 466 to 547, deleting the Dbl 
homology (DH) domain), p115dPH (1-720, deleting the C terminus and the pleckstrin 
homology (PH) domain), p115RGS (1-466, deleting both DH and PH domains), were cloned 
into the pcDNA3 mammalian expression vector as reported (38). The RhoA alleles (wild 
type (WT), the constitutively active (CA) 63L mutant and its effector domain mutants, and 
the dominant negative 19N mutant), lacZ, and CA mutant Cdc42 cDNAs were cloned in the 
pAX142 mammalian expression vector (39). The pNL4-3 plasmid encodes the entire HIV-1 
genome DNA in pUC18 (40). The pNL4.Luc.R−E− plasmid was obtained from the National 
Institutes of Health (NIH) AIDS Research and Reference Reagent Program (41). Human 
CD4 cDNA (T4-pMV7; Ref. 42) was also obtained from NIH. The RhoA (63L) effector 
domain mutants were constructed by site-directed mutagenesis of the RhoA63L gene and all 
were subcloned in the pcDNA3 vector.
293T and HeLa-MAGI cells (NIH AIDS Research and Reference Reagent Program; Ref. 
43) were maintained in DMEM supplemented with 10% FBS. Jurkat T cells (kindly 
provided by G. Crabtree, Stanford, CA) were maintained in RPMI 1640 supplemented with 
10% FBS.
HIV-1 production and replication in transfected human cells
Transient production of HIV-1 was performed by transfecting the HIV-1 provirus NL4-3 (1 
μg) with pcDNA3 vector (1 μg) or p115, Gα13, and RhoA derivatives (1 μg) and pAX142-
lacZ (0.1 μg) in 293T cells in 6-well plates with LipofectAMINE (or 0.5 μg each with 
Effectene; Qiagen, Santa Clarita, CA). At 40–50 h after transfection, HIV-1 virions in the 
culture supernatant were measured by RT or p24 assays (44) and infectious units were 
determined by titering the supernatant on HeLa-CD4-LTR-lacZ cells (MAGI) as described 
previously (43).
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HIV-1 infection assay was performed as follows. T4-pMV7 DNA was transfected into 293T 
cells with or without p115-RhoGEF (or RhoA). About 30% of transfected cells showed CD4 
expression as determined by FACS at 24 h after transfection. NL4-3 viral stocks (50,000 
cpm of RT activity) were used to infect the transfected cells at 24 h after transfection. HIV-1 
replication (supernatant RT activity) was measured at 3–4 days after infection.
To analyze HIV-1 gene expression in transfected cells, 1 μg of pNL4.Luc was cotransfected 
into 293T cells with 1 μg of pcDNA3 vector or 1 μg of the p115 (or RhoA) genes. Cell 
extracts were analyzed at 48 h after transfection for luciferase activity with a kit (Promega, 
Madison, WI). The pAX142-lacZ reporter plasmid (39) was included in the transfection mix 
and β-galactosidase activity was measured. The pAX142 promoter has been reported 
previously to be unaffected by Dbl family proteins (39, 45).
To analyze HIV-Luc gene expression in human T cells, Jurkat T cells were transfected with 
the Superfect reagents (Qiagen). The transfection mix included 0.3 μg of pNL4.Luc DNA, 
0.3 μg pAX142-lacZ, and various amounts (0, 0.3, 0.6, or 0.9 μg) of p115FL or CA RhoA 
DNA. Total DNA was adjusted to 1.5 μg with vector DNA in each transfection. Luciferase 
and β-galactosidase activity was measured at 48 h after transfection.
Expression of RhoA (or p115) proteins in transfected cells was confirmed by Western blot 
assays with RhoA (or p115)-specific Abs (21, 38).
Results
Activation of p115-RhoGEF suppresses HIV-1 replication
To test the possibility that p115-RhoGEF is involved in regulating HIV-1 replication, we 
studied the effect of p115-RhoGEF on HIV-1 replication in a transient HIV-1 replication 
assay. Ectopic expression of WT (p115FL) or an active mutant (p115dN; Ref. 38) of p115-
RhoGEF significantly inhibited HIV-1 replication from a cotransfected HIV-1 genome (Fig. 
1, A–C). Both virion-associated p24 Ag (Fig. 1A) and RT activity (Fig. 1B) and infectious 
unit (Fig. 1C) assays showed a significant reduction (5- to 10-fold) in HIV-1 production. In 
addition, HIV-1 replication initiated by infection was also inhibited by p115-RhoGEF. 
When 293T cells expressing CD4 and/or p115-RhoGEF were infected with HIV-1 (NL4-3), 
p115 also showed significant inhibition (~5-fold) of HIV-1 replication (Fig. 1D). Similar 
levels of CD4 expression were detected in cells cotransfected with T4-pCM7 and vector or 
p115-RhoGEF (data not shown). Therefore, p115-RhoGEF inhibited HIV-1 replication in 
both transfection and infection assays.
Like all Rho-specific GEFs (or Dbl family proteins; reviewed in Refs. 3 and 11), p115-
RhoGEF contains a DH and a PH domain and demonstrates transforming activity in 
NIH3T3 cells. The DH domain is involved in the nucleotide exchange activity and the PH 
domain determines its membrane association. Both domains are required for the 
transforming activity (11, 46, 47). To define the function of p115-RhoGEF involved in the 
inhibition, a number of p115 deletion mutants were tested. The DH domain of p115 is 
required for the inhibition of HIV-1 replication because deletion of the DH domain 
abolished its ability to inhibit HIV-1 replication (Fig. 2, A and C). The PH domain was also 
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required since p115-dPH also lost activity in inhibiting HIV-1 replication. Thus, membrane 
association of p115-RhoGEF is required for the activity. The RGS domain of p115-
RhoGEF, which functions as a GAP to inhibit its own activator Gα13 (48, 49), was not 
required for the inhibition. To show that the inhibition of HIV-1 replication by p115 is not 
due to its cytotoxicity, a cotransfected pAX142-lacZ reporter gene, which is not affected by 
Dbl family proteins (39), was not inhibited by p115-RhoGEF (Fig. 2B). This control also 
showed that transfection efficiency was not affected by p115 and/or HIV-1.
To demonstrate that activation of the endogenous p115-Rho-GEF can inhibit HIV-1 
replication, its specific upstream G protein activator was expressed in the HIV-1 replication 
assay. Ectopic expression of both WT and CA Gα13, which specifically activates p115-
RhoGEF activity (15), led to inhibition of HIV-1 replication (Fig. 3A). Thus, activation of 
endogenous p115-RhoGEF by its upstream G protein also leads to inhibition of HIV-1 
replication.
RhoA activity is required for the inhibition of HIV-1 replication
We confirmed that RhoA-dependent signaling was required for inhibition. Thus, the 
dominant negative mutant of RhoA19N counteracted the inhibitory activity of Gα13 on 
HIV-1 replication (Fig. 3B). To show the specificity of RhoA19N, a cotransfected control 
pAX142-lacZ reporter gene was not significantly affected by RhoA19N (data not shown).
To further confirm that RhoA signaling is involved in the inhibition, we directly 
coexpressed different alleles of RhoA with the HIV-1 genome (pNL4-3) in 293T cells (Fig. 
3C). Both the CA active form of RhoA (63L) and the WT RhoA showed significant 
inhibitory activity (5- to 10-fold) on HIV-1 replication. The negative mutant of RhoA (19N), 
however, showed no significant inhibitory activity.
Both RhoA and p115-RhoGEF inhibit HIV-1 gene expression
RhoA may affect many steps of HIV-1 replication such as viral gene expression, virion 
assembly, and release. To study the mechanism of HIV-1 inhibition mediated by RhoA, we 
analyzed reporter gene expression from an HIV-1 genome (pNL4-Luc), which lacks a 
functional env gene and expresses the luciferase gene in the nef region of HIV-1 (41). Both 
p115-RhoGEF and RhoA (63L) reduced the luciferase gene expression (~5-fold) when 
coexpressed in 293T cells (Fig. 4A). To show that RhoA is specifically involved, a CA 
mutant of Cdc42 (a closely related Rho GTPase; Ref. 39) did not inhibit HIV-1 gene 
expression (Fig. 4A). Both the RhoA and Cdc42 genes showed significant induction of SRF 
(Ref. 39 and data not shown). Therefore, signaling pathways mediated by RhoA, but not 
Cdc42, inhibited HIV-1 replication.
To demonstrate the inhibitory activity of RhoA and p115 in human T cells, similar 
transfection experiments were performed in the Jurkat T cell line with pNL4-Luc. 
Expression of HIV-encoded luciferase was inhibited by coexpression of p115-RhoGEF or 
the CA RhoA (63L) mutant in a dosage-dependent fashion (Fig. 4B). A cotransfected control 
reporter gene (pAX142-lacZ) was not significantly inhibited, demonstrating the specificity 
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of the inhibition (data not shown). Thus, RhoA activation also inhibited HIV-1 gene 
expression in human T cells.
A distinct RhoA effector pathway is involved
Effector domain mutants of RhoA have provided useful reagents to determine whether 
distinct RhoA-mediated functions are promoted by shared or distinct effector pathways (21, 
22). To define the specific RhoA effector activity involved in the inhibition of HIV-1 
replication, we constructed a series of effector domain mutants of RhoA63L (Fig. 5A). All 
RhoA mutant genes expressed similar levels of RhoA proteins (Fig. 5B and data not shown).
When their activity to inhibit HIV-1 replication was tested, a distinct profile of RhoA 
mutants was observed (Fig. 5C and Table I). Although it has impaired activity in 
transformation of NIH3T3 cells, SRF activation, and actin stress fiber formation (Ref. 21; 
Table I and data not shown), the RhoA E40W mutant showed efficient inhibition of HIV-1 
replication (Fig. 5C). Thus, the effector(s) required for these RhoA activities is distinct from 
the effector(s) required to inhibit HIV-1 replication. Furthermore, the RhoA F39L mutant, 
similar to the RhoA E40W mutant in cell transformation, but still with low or normal 
activity in SRF activation and actin stress fiber formation (21, 22), showed significantly 
reduced inhibition of HIV-1 replication (Fig. 5C). Thus, activation of SRF (partially) and 
actin stress fiber formation by RhoA is neither necessary nor sufficient to inhibit HIV-1 
replication. These results suggest that the HIV-1 inhibitory activity of RhoA is genetically 
separable from its activity in transformation of NIH3T3 cells, activation of SRF, and actin 
stress fiber formation. A unique RhoA effector pathway, which is defective in the RhoA 
F39L mutant, is involved in the inhibition.
Discussion
We report here that HIV-1 replication can be inhibited by p115-RhoGEF, which is a specific 
activator of the RhoA GTPase and preferentially expressed in lymphoid tissues (38, 50). 
Both the upstream activator (Gα13) and downstream effector (RhoA) of p115 can also 
down-regulate HIV-1 replication. Furthermore, we present evidence that a novel RhoA 
effector activity is involved. These findings reveal a novel signal transduction pathway that 
is involved in regulating HIV-1 replication and pathogenesis.
Inhibition of HIV-1 replication by RhoA may occur at different steps of the HIV-1 gene 
expression. First, RhoA may coordinate HIV-1 transcription during infection since RhoA is 
involved in the regulation of transcription factors such as SRF (7) and NF-κB (8). This 
hypothesis agrees with the finding that RhoA inhibited HIV-1 gene expression (Fig. 4). 
However, activation of NF-κB by RhoA should enhance HIV-1 gene expression (32). Other 
transcription factors important for HIV-1 gene expression may be negatively regulated by 
RhoA. Alternatively, repression factors may be induced by RhoA activation. In addition, 
posttranscriptional steps such as RNA stability, splicing, and transport may also be affected 
by RhoA. Second, RhoA is involved in regulating cell cycle progression (9, 10, 28). Possible 
modulation of cell cycle progression by p115-RhoGEF and RhoA may also affect HIV-1 
replication in these target cells (51). However, since RhoA appears to demonstrate different 
Wang et al. Page 6













activities in different cell types, it will be important to study the effects of p115RhoGEF and 
RhoA in primary T and macrophage cells.
Gα13 has recently been identified as an upstream activator of p115-RhoGEF (48). Its 
possible activation by putative G proteincoupled receptor (GPCRs, including the HIV-1 
coreceptors; Ref. 52) suggests that extracellular factors (e.g., chemokines and HIV-1 env 
proteins) may modulate the Gα13/p115-RhoGEF/RhoA signaling cascade to affect HIV-1 
replication (Fig. 6). Further elucidation of the interaction among the specific GPCR, Gα13, 
and p115-RhoGEF will provide valuable information about the mechanism of possible 
GPCR-mediated RhoA activation and its effect on HIV-1 replication.
The transmembrane glycoprotein (TM or gp41) of HIV-1 contains a long cytoplasmic 
domain (gp41C). Its function is not clear but has been implicated in regulating HIV-1 
replication and cytopathogenicity (36). We recently demonstrated that HIV-1 gp41C 
interacted with the C-terminal domain of p115-RhoGEF and that the interaction led to 
inhibition of p115 activity. Mutations in gp41C that disrupted the interaction between gp41C 
and p115 led to impaired HIV-1 replication in various T cell lines (37). Thus, it is possible 
that one of the functions of HIV-1 gp41C is to counteract the inhibitory activity of p115/
RhoA to enhance viral replication. However, the provirus bearing the mutations in gp41C 
produced WT levels of HIV virions when transfected in 293T cells (37), suggesting that lack 
of gp41C interaction (and inhibition) with p115 had no effect on HIV gene expression. 
Therefore, the inhibitory effect of gp41C on p115-mediated RhoA activation may not play a 
significant role in HIV-1 production in transfected 293T cells. We are currently 
investigating the mechanism of the impaired replication of the HIV mutants in T cell lines 
and in the SCID-hu Thy/Liv mouse.
The RhoA activity in inhibiting HIV-1 replication is distinct from its activities in cell 
transformation, SRF activation, and actin stress fiber formation. As proposed previously 
(21), the RhoA effector ROK is involved in cell transformation and partly in SRF activation 
and actin stress fiber formation (Fig. 6). Both the F39L and the E40W mutants have lost 
their interaction with ROK (21). An additional effector (X, defective in the E40W mutant) is 
involved in mediating SRF activation. A distinct effector (Y) is also proposed to mediate 
actin stress fiber formation (21, 22). In this report, a novel RhoA effector activity (Z) 
involved in the inhibition of HIV-1 replication is proposed. Mutant F39L is defective in the 
putative interaction (or activation) with Z, which will be useful to define the novel RhoA 
effector (Z).
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Inhibition of HIV-1 replication by p115-RhoGEF. The HIV-1 proviral genome pNL4–3 was 
cotransfected with pcDNA3 (vector), WT (p115FL), or activated the p115-RhoGEF 
(p115dN) gene into 293T cells. HIV-1 production in the culture medium was measured at 48 
h after transfection by p24 ELISA (A) or RT assays (B). Infectious units (C) were measured 
by titration of the culture supernatant on MAGI cells (43). Data shown are representative of 
at least three independent experiments. In D, HIV-1 infection assay was performed in 293T 
cells expressing human CD4 with the p115FL gene or with vector DNA. HIV-1 replication 
(RT, 103 cpm/ml) was measured at 4 days after infection. Data presented represent three 
independent experiments. SDs of duplicate samples are shown as error bars.
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The GEF activity of p115-RhoGEF is required for the inhibition. Different mutants of p115-
RhoGEF or the FGD1 gene were cotransfected with the HIV-1 genome (pNL4-3). HIV-1 
replication (p24, ng/ml) was measured 48 h after transfection (A). At least three independent 
experiments were performed with similar results. A cotransfected pAX-lacZ gene (45) was 
included as an internal control (B). A number of p115 deletion mutants were tested and their 
activity in RhoA activation (GEF activity and cell transformation; Ref. 38 and unpublished 
results) and HIV-1 inhibition are summarized (C). The numbers indicate the amino acid 
positions of the mutants. The N-terminal 250-amino acid residues encode the RGS domain 
(GAP of Gα13). DH and PH domains are indicated. +, >75% of WT p115 (FL) activity; −, 
<20% of WT p115 (FL) activity.
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Activation of endogenous p115-RhoGEF and RhoA by Gα13 leads to HIV-1 inhibition. A, 
WT Gα13 or CA Gα13 was cotrans-fected with pNL4-3 and HIV-1 replication (RT × 103 
cpm/ml) was measured. The experiments were performed three times with similar results. 
Error bars represent SDs. Gα13WT, Gα13CA, and vector indicate samples transfected with 
WT Gα13, CA Gα13, and pcDNA3 vector, respectively. B, RhoA (19N) counteracted the 
HIV-1 inhibitory activity of Gα13. pNL4-3 and Gα13CA were cotransfected with the 
dominant negative RhoA mutant RhoA (19N). HIV-1 replication (RT × 103 cpm/ml) was 
measured. Three independent experiments were performed with similar results. Error bars 
indicate SDs. C, Active RhoA proteins inhibit HIV-1 replication. pNL4-3 was cotransfected 
with vector, WT RhoA, mutant RhoA (19N), or the CA RhoA (63L) gene and HIV-1 
replication was measured by p24, RT, or infectious units (IU). Relative levels of HIV-1 
replication are presented and samples cotransfected with vector DNA were expressed as 
100%. Three independent experiments were performed and SDs are shown as error bars.
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Both RhoA and p115 inhibit HIV-1 gene expression. A, Inhibition of luciferase gene 
expression from the pNL4.Luc genome in 293T cells. The pNL4.Luc genome was 
cotransfected into 293T cells with pcDNA3 vector (vector), p115FL (p115FL), p115dN 
(p115dN), the CA RhoA (63L), or a CA Cdc42. The level of luciferase expression (relative 
light units, RLU) was measured. Mock (pcDNA3 vector only)-transfected cells were used as 
background. Experiments were performed in duplicate and repeated three times. SDs of 
duplicate samples are shown as error bars. B, Inhibition of HIV-1 gene expression in human 
T cells. The pNL4.Luc plasmid was transfected into Jurkat T cells with vector DNA or 
various amounts of plasmid DNA encoding p115FL or the CA mutant RhoA63L (RhoA-
CA). The experiments were repeated three times with similar results.
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A distinct RhoA effector activity is involved in HIV-1 inhibition. A, The RhoA effector 
domain and mutants. Amino acids are designated with a one-letter code and numbers in the 
RhoA coding region are indicated. The mutated amino acids are underlined. RhoA mutants 
D28N, V33E, F39L, and D45Q have been reported previously (22). RhoA mutants F39L 
and E40W have also been described previously (21). RhoA mutants D45N and E47M were 
constructed for this study. B, RhoA protein expression by various RhoA effector mutants. 
RhoA proteins were detected in transfected 293T cells with a RhoA-specific antiserum. The 
lower band in mock-transfected cells is nonspecific. All RhoA effector domain mutations 
were in the activated RhoA63L mutant background. The lane marked RhoA indicates 
samples transfected with the WT RhoA gene. C, Inhibition of HIV-1 replication by different 
RhoA effector mutants. pNL4-3 was cotransfected with vector or different RhoA mutant 
derivatives. HIV-1 production was measured by RT or infectious units assays. The relative 
HIV-1 replication is presented as percentage of vector controls (100%). 63L, RhoA (63L). 
Three independent experiments were performed with similar results. SDs of duplicate 
samples are shown as error bars.
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The RhoA activation pathway and HIV-1 replication. The putative GPCR linking Gα13 and 
the RhoA-signaling pathway may trigger a cascade of events to modulate HIV-1 replication, 
actin cytoskeletal organization (actin fiber), transcription activation (SRF), cell survival, and 
growth. Both the F39L and E40W mutants are defective in interacting with ROK and in 
promoting transformation of NIH3T3 cells (21). The E40W mutant is also defective in SRF 
activation (X). The F39L mutant is only partially defective in SRF activation (21, 22). The 
Y effector pathway is proposed to mediate actin stress fiber formation and is defective in the 
E40W mutant (21), but functional in the F39L mutant (21, 22). The HIV-1 inhibitory 
activity is defective in the F39L mutant, but functional in the E40W mutant. A novel 
effector (Z) pathway is proposed to mediate the HIV-1 inhibitory function.
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RhoA (63L) + ++ + +
D28N + ++ + +
F39L −(+) + − −
E40W − − − +
D45N + ++ + +
E47M + ++ + +
a
RhoA(63L) and the mutant derivatives are described in Fig. 6A.
b
Based on data from two different reports. F39L is partially defective in promoting actin stress fiber in one study (21), but is normal in the other 
(22).
c
Activation of SRF is measured with a reporter gene under control of the SRF-dependent promoter (Refs. 21 and 22 and data not shown). ++, 
50-100% of wild-type activity; +, 20-50% of wild-type activity; −, <20% of wild-type activity.
d
Transformation of NIH3T3 cells by various RhoA alleles is summarized (Refs. 21 and 22 and data not shown). +, 50-100%) of wild-type activity; 
−, <20%) of wild-type activity.
e
Inhibition of HIV-1 replication by RhoA was measured by RT or infectious units assays (Fig. 5C). +, 50-100%) of wild-type activity; −, <20%) of 
wild-type activity.
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